Initial Phase 2 Results for Myriad Pharmaceuticals' Azixa(TM) (MPC-6827) in Metastatic Melanoma
18 nov. 2009 08h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 18, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of initial clinical data from an ongoing Phase 2a study of Azixa(TM)...
Myriad Pharmaceuticals Confirms That MPC-3100, a Fully-Synthetic Hsp90 Inhibitor, is Orally-Bioavailable in Patients in Phase 1 Studies
16 nov. 2009 08h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 16, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preliminary phase 1 data for MPC-3100, its fully-synthetic small...
Myriad Pharmaceuticals Reports First Quarter FY' 2010 Financial Results
12 nov. 2009 17h21 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 12, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its first fiscal quarter ended September 30, 2009.
"We are pleased...
Myriad Pharmaceuticals' Azixa(TM) is Efficacious in a Model of Human Brain Cancer and Its Activity is Additive With Avastin(R)
23 oct. 2009 14h30 HE
|
Myrexis, Inc.
SALT LAKE CITY, Oct. 23, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the presentation of non-clinical data demonstrating the potent anti-cancer activity of...
Myriad Pharmaceuticals Announces Presentation on Azixa(TM) at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors
20 oct. 2009 08h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Oct. 20, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that an abstract has been selected for oral presentation at the 2009 Joint Meeting of the...
Myriad Pharmaceuticals Announces the Identification of an IND Candidate for the Treatment of Cancer, Obesity, and Diabetes
13 oct. 2009 16h20 HE
|
Myrexis, Inc.
SALT LAKE CITY, Oct. 13, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the identification of an Investigational New Drug (IND) candidate targeting a novel...
Myriad Pharmaceuticals Elects Timothy R. Franson, M.D. to Its Board of Directors
15 sept. 2009 08h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 15, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) announced today that it has elected Timothy R. Franson, M.D. to its Board of Directors. Dr. Franson's term...
Myriad Pharmaceutical's Tablet Formulation of MPC-4326 Reduces Viral Load in HIV-1 Patients
14 sept. 2009 14h42 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 14, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the presentation of two abstracts detailing positive data for MPC-4326, its novel...
Myriad Pharmaceuticals Announces Two Abstracts Selected for Presentation At 2009 ICAAC Annual Meeting
10 sept. 2009 18h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that two abstracts have been selected for presentation at the Interscience Conference on...
Myriad Pharmaceuticals, Inc. to Present At Upcoming Investor Conferences
03 sept. 2009 18h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 3, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a company focused on discovering, developing and commercializing novel, small molecule drugs for the...